Amyloid Treatment & Research Program
Donate Contact
About Patients Doctors Researchers
About Patients Doctors Researchers

2003

Allan, L. L., K. K. Mann, R. A. Matulka, H. Y. Ryu, J. J. Schlezinger, and D. H. Sherr
Bone marrow stromal-B cell interactions in polycyclic aromatic hydrocarbon-induced pro/pre-B cell apoptosis. Toxicol Sci, 76:357, 2003.

Berghoff M, Kathpal M, Khan F, Skinner M, Falk R, Freeman R
Endothelial dysfunction precedes C-fiber abnormalities AL amyloidosis.  Annals of Neurology 53: 725-730, 2003.

Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH
Persistent pleural effusions in primary systemic amyloidosis.  Chest 124: 969-977, 2003.

Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM
High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.  Kidney International 63: 1051-1057, 2003.

Connors, L. H.; Lim, A.; Prokaeva, T.; Roskens, V. A.; Costello, C. E.
Tabulation of Human Transthyretin (TTR) Variants, 2003.  Amyloid, J. Prot. Fold. Disord.  10: 160-184, 2003.

Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DW, Skinner M, Dember LM
Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.  Kidney International 63: 1868-1873, 2003.

Hammarström, P.; Y. Sekijima, Y.; White, J. T.; Wiseman, R. L.; Lim, A.; Costello, C. E.; Altland, K.; Garzuly, F.; Budka, H.; Kelly, J. W.
D18G Transthyretin is Monomeric, Aggregation Prone, and Not-Detectable in Plasma and Cerebrospinal Fluid - A Prescription for CNS Amyloidosis?  Biochemistry  42: 6656-6663, 2003.

Jensen, B. A., R. J. Leeman, J. J. Schlezinger, and D. H. Sherr
Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells. Env. Health. J.2:16, 2003.

Lim A, Prokaeva T, McComb ME, Connors LH, Skinner M, Costello CE
Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.  Protein Science, 12: 1775-1785, 2003.

Lim, A.; Sengupta, S.; McComb, M. E.; Théberge, R.; Wilson, W. G.; Costello, C. E.; Jacobsen, D. W.
In Vitro and In Vivo Interactions of Homocysteine with Human Plasma Transthyretin. J. Biol. Chem. 278: 49707-49713, 2003.

Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V
Spontaneous rupture of the spleen in AL amyloidosis.  Am J Hem, 74: 131-135, 2003.

Seldin DC
Diagnosis and treatment of AL amyloidosis. Clinical Advances in Hematology and Oncology, 1:154-155, 2003.

Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, O’Hara C, Fennessey S, Finn KT, Wright DG, Skinner M, Sanchorawala V
Tolerability and efficacy of thalidomide for the treatment of patients with AL amyloidosis.  Clinical Lymphoma 3: 241-246, 2003.

Swan N, Skinner M, O’Hara CJ
Bone marrow core biopsies in AL (Primary) amyloidosis
a morphologic and immunohistochemical study of 100 patients. Am J Clin Path 120: 610-616, 2003.

Researchers
Boston University
Boston University
       This Site   BU  

Boston University | Amyloid Treatment & Research Program | February 13, 2006

 
Boston University home page Boston University home page Amyloid Treatment & Research Program